



The TIMI Trials

CLARITY-TIMI 28

OBJECTIVE: To assess the efficacy and safety of adding clopidogrel to a standard fibrinolytic regimen that includes aspirin.

1. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. *Am Heart J* 2005;149:227-33.
2. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys M, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005;352:1179-89.
3. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolysis: The PCI-CLARITY study. *JAMA* 2005;294:1224-32.
4. Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E. Angiographic and clinical outcomes in patients receiving low-molecular weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial. *Circulation* 2005;112:3846-54.
5. Scirica BM, Sabatine MS, Murphy SA, Kirtane A, Aroesty J, Cannon CP, Gibson CM. Improved Findings on Late Angiography Are Associated with Lower Rates of New Q-waves in Patients Receiving Fibrinolysis for ST Elevation Myocardial Infarction - Results From CLARITY-TIMI 28. *Circulation* 2005; 112(17 Suppl II):II-693.
6. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. Correlates and outcomes associated with ST segment resolution after fibrinolytic therapy. Results from the ECG CLARITY - TIMI 28 substudy. *Circulation* 2005;112:II:486.
7. Kirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CM. Differences between streptokinase and fibrin-specific fibrinolytic therapy when co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudy. *Circulation* 2005;112:II:567.
8. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: The ECG CLARITY-TIMI 28 study. *J Am Coll Cardiol* 2006;48:37-42.
9. Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CM. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. *Eur Heart J* 2006;27:2040-5.
10. Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP. Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated with Higher Platelet Counts in Patients with ST-Elevation Myocardial Infarction: Results from CLARITY-TIMI 28. *Am J Cardiol* 2006;98:761-3.
11. Ahmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. *J Am Coll Cardiol* 2006;47:159A.
12. O'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CM. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: CLARITY-TIMI 28 substudy. *J Am Coll Cardiol* 2006;47:222A.
13. Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CP. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 Trial. *J Thromb Thrombolysis* 2006;22:161-4.

14. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. *J Thromb Thrombolysis* 2007;24:85-91.
15. Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME, for the TIMI Study Group. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2008;51:546-51.
16. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). *Am J Cardiol* 2008;101:303-7.
17. Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald E. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. *Am J Cardiol* 2008;101:1232-8.
18. Gibson CM, Murphy SA, Kirtane AJ, Aroesty JM, Sabatine MS, Cannon CP, Braunwald E. Effects of pre-treatment with clopidogrel on non-emergent percutaneous coronary intervention after fibrinolytic administration in ST elevation myocardial infarction: A Clopidogrel as Adjustive Reperfusion Therapy - Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. *Am Heart J* 2008;155:133-9.
19. O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, Sabatine MS. Association Between Baseline Neutrophil Count, Clopidogrel Therapy, and Clinical and Angiographic Outcomes in Patients with ST-Elevation Myocardial Infarction Receiving Fibrinolytic Therapy. *Eur Heart J* 2008;29:984-91.
20. [Sabatine MS](#), [Hamdalla HN](#), [Mehta SR](#), [Fox KA](#), [Topol EJ](#), [Steinhubl SR](#), [Cannon CP](#). Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. *Am Heart J* 2008;155:910-7.
21. [Sabatine MS](#), [Morrow DA](#), [Higgins LJ](#), [MacGillivray C](#), [Guo W](#), [Bode C](#), [Rifai N](#), [Cannon CP](#), [Gerszten RE](#), [Lee RT](#). Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. [Circulation](#) 2008;117:1936-44.